Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with (177)Lu-PSMA radioligand therapy

PSMA based radioligand is a new investigational drug for treatment of metastatic multidrug-resistant and castration-resistant prostate cancer. Prognostic factors point to above and below average overall survival (OS) after the treatment. Kessel et al. [Theranostics 2019;9:4841-8] reported for the fi...

Descripción completa

Detalles Bibliográficos
Autores principales: von Eyben, Finn Edler, Kulkarni, Harshad R., Baum, Richard P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7163457/
https://www.ncbi.nlm.nih.gov/pubmed/32308757
http://dx.doi.org/10.7150/thno.44568

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7163457/
https://www.ncbi.nlm.nih.gov/pubmed/32308757
http://dx.doi.org/10.7150/thno.44568

Ejemplares similares